Last reviewed · How we verify
NCT03396016
Plasmatic Factor V as a Predictor of Graft Dysfunction After Liver Transplantation
trial in Liver Transplant Failure in 140 participants. Status unknown.
10 April 2021
Quick facts
| Lead sponsor | University Health Network, Toronto |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 140 |
| Start date | 18 April 2018 |
| Primary completion | 10 April 2021 |
| Estimated completion | 28 February 2023 |
| Sites | 1 location across Canada |
Conditions studied
- Liver Transplant Failure — all drugs for Liver Transplant Failure →
Sponsor
University Health Network, Toronto
Who can join
18 and older, any sex, with Liver Transplant Failure. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Factor V is a coagulation cofactor that is primarily produced by the liver. Previous data has suggested a correlation between factor V levels and graft dysfunction. The investigators hypothesize that Factor V may be a reliable biomarker for hepatic function after LT. Therefore, the aim of this study is to validate the use of Factor V as a predictor of graft dysfunction after LT. This is a single-center prospective validation study. Patients undergoing LT at the University Health Network will have plasmatic Factor V levels measured during postoperative week 1. Patients will be followed up to 12 months. The study outcomes will be early graft dysfunction, and graft and patient survival. Graft loss will be defined as need for retransplantation in the study period.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Nucleic acid biomarkers to assess graft injury after liver transplantation.
Bardhi E, McDaniels J, Rousselle T, Maluf DG, et al · · 2022 · cited 15× · PMID 35243279 · DOI 10.1016/j.jhepr.2022.100439
Verify or expand the search:
- PubMed search for NCT03396016
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Liver Transplant Failure
Currently open trials in the same condition.
- NCT05866796 — Serum GLYcomics to Predict Graft Loss and Mortality After Liver Transplantation · recruiting
Other University Health Network, Toronto trials
Trials by the same sponsor.
- NCT06831032 — Elective Adaptive Radiation With SBRT for Improved DurabilitY of Response · NA · recruiting
- NCT06634056 — Pneumonitis Prevention Protocol Using Pentoxifylline and α-tocopherol In Stage III Non-Small Cell Lung Cancer Patients U · Phase 2 · not yet recruiting
- NCT06836726 — Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resis · Phase 2 · not yet recruiting
- NCT07515651 — Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas · Phase 2 · not yet recruiting
- NCT07509450 — Fecal Microbiota Transplantation in Patients Undergoing Chimeric Antigen Receptor T-cell Therapy and Allogeneic Stem Cel · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03396016 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University Health Network, Toronto
- Last refreshed: 8 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03396016.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing